CNP520

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Alzheimer's DiseaseAlzheimers Disease

Phase 2

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

TerminatedNCT02565511

Novartis PharmaceuticalsAlzheimers Disease

Start: 2015-11-30End: 2020-04-30Updated: 2021-07-08

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

CompletedNCT02576639

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2015-08-10End: 2016-03-11Updated: 2017-08-11

Related Papers

Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.

2025-11-27

P4‐654: CONNECT 4 <i>APOE</i>: A RANDOMIZED STUDY OF PHONE VERSUS VIDEOCONFERENCE DELIVERY OF <i>APOE</i> GENOTYPE DISCLOSURE IN THE GENERATION STUDY

Alzheimer s & Dementia2019-07-011 citations

The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.

2017-01-0126 citations